Home » Newsletters » BioWorld

BioWorld

May 13, 2008

View Archived Issues

Despite Tough Market, Aldagen's IPO Seeks $81M for Cell Therapy

With its lead cell therapy program in a pivotal study, Aldagen Inc. has decided to brave the public markets. (BioWorld Today) Read More

Cell Genesys Snagging $30M to Push Late-Stage GVAX

Long-Term UK Bio Investor Prelude Trust Calling it Quits

Novelos Antitumor Drug Hits Efficacy Mark Early in Trial

Other News To Note

Earnings Roundup

U.S. Patent Disclosures

Clinic Roundup